Citation :

Ramineni Snehamrutha, 2024. "Development and In-Vitro Evaluation of a Sustained-Release Transdermal Patch for Improved Patient Adherence" ESP International Journal of Advancements in Science & Technology (ESP-IJAST) Volume 2, Issue 4: 34-43.

Abstract :

Transdermal drug delivery systems (TDDS) are a new, patient-friendly way to treat long-term chronic illnesses compared to traditional systemic dose types of medicine administration. TDDS can decrease the dosing schedule and increase the regularity of therapy by avoiding first-pass metabolism and allowing patients to control drug delivery. Nevertheless, a significant number of commercially current transdermal preparations continue to be high drug loaded and demand high frequency of application that can potentially adversely affect patient compliance and safety. In that regard, sustained-release transdermal patches provide a valid approach in overcoming these constraints. This paper is a review of concepts of drug delivery through transdermal patches, special focus is given to the sustained-release systems and how they can help increase patient compliance. Evaluation techniques, both in vitro and ex vivo, such as skin deposition study using Franz diffusion cells and drug-excipient compatibility are discussed alongside important formulation considerations like polymer choice. In addition, the effect of the sustained-release transdermal patches on patient compliance is examined through the comparison of the benefits of the patches over oral and injectable treatments with respect to convenience, non-invasiveness, and controlled drug delivery. In general, sustained-release transdermal systems show a lot of potential to enhance the adherence level, reduce dose-related adverse effects, and maximize long-term therapeutic effects, which could be considered important in the future development of patient-centric drug delivery platforms.

References :

[1] R. Vashishth, M. Chuong, J. Duarte, Y. Gharat, and S. Kerr, “Two Sustained Release Membranes Used in Formulating Low Strength Testosterone Reservoir Transdermal Patches,” Curr. Drug Deliv., vol. 20, 2023, doi: 10.2174/1567201820666230316115921.

[2] P. Serrano Castañeda et al., “Design and evaluation of a transdermal patch with Atorvastatin,” Farmacia, vol. 65, pp. 908–916, 2017.

[3] A. Tripathi, P. Tyagi, A. Vyas, B. Gidwani, A. Chandekar, and H. Sharma, “In vitro evaluation of Transdermal Patch of Palonosetron for Antiemetic Therapy,” Int. J. Drug Deliv., vol. 9, p. 119, 2018, doi: 10.5138/09750215.2186.

[4] S. Afreen et al., “Design and in-vitro evaluation of controlled release tri-layer venlafaxine hydrochloride transdermal patch,” Asian J. Pharm. Clin. Res., vol. 8, pp. 271–277, 2015.

[5] J. He, Y. Zhang, X. Yu, and C. Xu, “Wearable patches for transdermal drug delivery,” Acta Pharm. Sin. B, vol. 13, no. 6, pp. 2298–2309, Jun. 2023, doi: 10.1016/j.apsb.2023.05.009.

[6] G. RK, “Transdermal Drug Delivery System: An Emphasis on Transdermal Patches,” Pharm. Drug Regul. Aff. J., vol. 6, no. 1, pp. 1–5, 2023, doi: 10.23880/pdraj-16000147.

[7] V. Rastogi and P. Yadav, “Transdermal drug delivery system: An overview,” Asian J. Pharm., vol. 6, p. 161, 2012, doi: 10.4103/0973-8398.104828.

[8] A. Ahuja, J. Gupta, and R. Gupta, “Miracles of Herbal Phytomedicines in Treatment of Skin Disorders: Natural Healthcare Perspective,” Infect. Disord. - Drug Targets, vol. 20, 2020, doi: 10.2174/1871526520666200622142710.

[9] Q. Tian, P. Quan, L. Fang, H. Xu, and C. Liu, “A molecular mechanism investigation of the transdermal/topical absorption classification system on the basis of drug skin permeation and skin retention,” Int. J. Pharm., vol. 608, p. 121082, Oct. 2021, doi: 10.1016/j.ijpharm.2021.121082.

[10] B. Monika, R. Amit, B. Sanjib, B. Alisha, P. Mihir, and T. Dhanushram, “Transdermal drug delivery system with formulation and evaluation aspects: Overview,” Res. J. Pharm. Technol., vol. 5, no. 9, pp. 1168–1176, 2012.

[11] V. Thakran, “A Review of 3D printing methods for pharmaceutical manufacturing : Technologies and applications,” Int. J. Sci. Res. Arch., vol. 04, no. 01, pp. 250–261, 2021, doi: 10.30574/ijsra.2021.4.1.0207.

[12] W. Zhao, L. Ma, S. Guo, J. Y. Liu, J. Piao, and M. Piao, “Transdermal drug delivery system of domperidone sustained-release coated microsphere gels: In vitro characterization and in vivo evaluation,” J. Drug Deliv. Sci. Technol., vol. 78, p. 103939, Dec. 2022, doi: 10.1016/j.jddst.2022.103939.

[13] X. Hou et al., “Recent advances in hyaluronic acid-based nanomedicines: Preparation and application in cancer therapy,” Carbohydr. Polym., vol. 292, p. 119662, Sep. 2022, doi: 10.1016/j.carbpol.2022.119662.

[14] S. Zsikó, E. Csányi, A. Kovács, M. Budai-Szűcs, A. Gácsi, and S. Berkó, “Methods to Evaluate Skin Penetration In Vitro,” Sci. Pharm., vol. 87, no. 3, 2019, doi: 10.3390/scipharm87030019.

[15] S. Dutt, “Importance of Patient Adherence and Compliance in the Present Day,” J. Bacteriol. Mycol. Open Access, vol. 4, no. 5, pp. 150–152, 2017, doi: 10.15406/jbmoa.2017.04.00106.

[16] Y. Macha, “A Review of Cloud-Based CRM Systems in Healthcare: Advances, Tools, Challenges, and Best Practices,” Int. J. Curr. Eng. Technol., vol. 12, no. 6, pp. 848–856, 2022, doi: 10.14741/ijcet/v.12.6.20.

[17] A. E. Kasahun, A. K. Sendekie, G. A. Mekonnen, F. D. Sema, L. K. Kemal, and R. B. Abebe, “Impact of Personal, Cultural and Religious Beliefs on Medication Adherence among Patients with Chronic Diseases at University Hospital in Northwest Ethiopia,” Patient Prefer. Adherence, vol. 16, no. July, pp. 1787–1803, 2022, doi: 10.2147/PPA.S370178.

[18] V. Pal, “Hybrid Quantum-Classical Machine Learning Architectures for Accelerated Drug Discover,” Int. J. Adv. Res. Sci. Commun. Technol., vol. 6, no. 2, pp. 1641–1653, 2021, doi: 10.48175/IJARSCT-6582M.

[19] G. Sarraf, “Privacy Preserving Blockchain for Healthcare: Addressing Security Challenges Through Decentralized Architecture,” Tech. Int. J. Eng. Res., vol. 10, no. 11, pp. 111–117, 2023, doi: 10.56975/tijer.v10i11.159993.

[20] W. F. Wong, K. P. Ang, G. Sethi, and C. Y. Looi, “Recent Advancement of Medical Patch for Transdermal Drug Delivery,” Medicina (B. Aires)., vol. 59, no. 4, p. 778, Apr. 2023, doi: 10.3390/medicina59040778.

[21] J. Schneider-Thoma et al., “Comparative efficacy and tolerability of 32 oral and long-acting injectable antipsychotics for the maintenance treatment of adults with schizophrenia: a systematic review and network meta-analysis,” Lancet, vol. 399, no. 10327, pp. 824–836, Feb. 2022, doi: 10.1016/S0140-6736(21)01997-8.

[22] E. D’Amico, A. Zanghì, and C. Avolio, “Injectable versus oral first-line multiple sclerosis therapies: knows and unknowns from observational studies,” Neural Regen. Res., vol. 17, no. 3, p. 567, 2022, doi: 10.4103/1673-5374.320985.

[23] I. Alissa et al., “Design, Development, and Evaluation of Treprostinil Embedded Adhesive Transdermal Patch,” Pharmaceutics, vol. 15, 2023, doi: 10.3390/pharmaceutics15041226.

[24] P. Sharma and M. Tailang, “Primaquine-loaded transdermal patch for treating malaria: design, development, and characterization,” Futur. J. Pharm. Sci., vol. 8, 2022, doi: 10.1186/s43094-022-00433-5.

[25] H. Hassam, M. Shoaib, R. Yousuf, F. Ramzan Ali, F. Siddiqui, and A. Irshad, “Formulation development and evaluation of nimesulide transdermal gel patch system,” Polym. Bull., vol. 79, 2022, doi: 10.1007/s00289-021-03764-0.

[26] N. Tadhi, H. Chopra, and G. Sharma, “Formulation and Evaluation of Transdermal patch of Methimazole,” Res. J. Pharm. Technol., pp. 4667–4672, 2021, doi: 10.52711/0974-360X.2021.00811.

[27] P. Verma, D. Bairagee, A. Somkuwar, M. Mehra, and M. Chhajed, “Formulation and Evaluation of Transdermal Patch of Glibenclamide,” Int. J. Pharm. Life Sci., vol. 11, pp. 6724–6737, 2020.

[28] L. Qiang, L.-J. Zhang, Y. Gao, C.-A. Gong, Q.-M. Xia, and S. Gao, “Preparation and in vitro evaluation of prolonged-release transdermal contraceptive patch containing drospirenone and ethinylestradiol,” Chinese J. New Drugs, vol. 28, pp. 87–93, 2019

Keywords :

Transdermal Drug Delivery Systems (TDDS), Sustained-Release Transdermal Patches, Patient Compliance, Chronic Disease Management, Controlled Drug Delivery, Polymer Selection.